BR0213043A - Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração - Google Patents
Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coraçãoInfo
- Publication number
- BR0213043A BR0213043A BR0213043-2A BR0213043A BR0213043A BR 0213043 A BR0213043 A BR 0213043A BR 0213043 A BR0213043 A BR 0213043A BR 0213043 A BR0213043 A BR 0213043A
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- myocardial
- treating
- preventing
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 title abstract 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002107 myocardial effect Effects 0.000 title 2
- 208000031229 Cardiomyopathies Diseases 0.000 title 1
- 208000021908 Myocardial disease Diseases 0.000 title 1
- 230000009091 contractile dysfunction Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 title 1
- 208000019622 heart disease Diseases 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 238000011820 transgenic animal model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32657601P | 2001-10-01 | 2001-10-01 | |
| US32801001P | 2001-10-08 | 2001-10-08 | |
| PCT/US2002/031496 WO2003029428A2 (en) | 2001-10-01 | 2002-10-01 | Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213043A true BR0213043A (pt) | 2004-10-05 |
Family
ID=26985461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213043-2A BR0213043A (pt) | 2001-10-01 | 2002-10-01 | Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7320959B2 (enExample) |
| EP (1) | EP1439849A4 (enExample) |
| JP (1) | JP2005504829A (enExample) |
| KR (1) | KR20040045041A (enExample) |
| CN (1) | CN1599622A (enExample) |
| AU (1) | AU2002341938B2 (enExample) |
| BR (1) | BR0213043A (enExample) |
| CA (1) | CA2462443A1 (enExample) |
| IL (1) | IL161231A0 (enExample) |
| MX (1) | MXPA04003040A (enExample) |
| NO (1) | NO20041331L (enExample) |
| NZ (1) | NZ532327A (enExample) |
| PL (1) | PL369104A1 (enExample) |
| WO (1) | WO2003029428A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255121A1 (en) * | 2004-11-02 | 2008-10-16 | Dainippon Sumitomo Pharma Co., Ltd. | Combination Drug for Treating Autoimmune Disease |
| CN107402307A (zh) * | 2008-04-09 | 2017-11-28 | B.R.A.H.M.S 有限公司 | 用于预测受损峰值耗氧量的内皮素1原 |
| US8841423B2 (en) * | 2008-04-28 | 2014-09-23 | University Of Iowa Research Foundation | Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II |
| US20090275514A1 (en) * | 2008-05-01 | 2009-11-05 | Anderson Mark E | Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation |
| WO2010135676A1 (en) * | 2009-05-22 | 2010-11-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Engineered biological pacemakers |
| US8440656B2 (en) * | 2009-06-22 | 2013-05-14 | University Of Iowa Research Foundation | Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity |
| EP3603658B1 (en) | 2009-10-05 | 2025-01-08 | Cornell University | Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy |
| CN105517549B (zh) | 2013-03-06 | 2018-11-23 | 阿略斯泰罗斯医疗公司 | CaMKII抑制剂和其用途 |
| DE102014201651A1 (de) * | 2014-01-30 | 2015-07-30 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen |
| CA2960101C (en) | 2014-09-05 | 2024-05-21 | Allosteros Therapeutics, Inc. | Substituted carboline derivative and compositions thereof useful as camkii inhibitors |
| WO2018031771A1 (en) | 2016-08-11 | 2018-02-15 | University Of Iowa Research Foundation | CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA |
| CN112972447B (zh) * | 2021-03-02 | 2022-09-23 | 扬州大学附属医院 | CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (enExample) * | 1968-10-17 | 1970-08-24 | ||
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| JP2001509808A (ja) * | 1997-01-31 | 2001-07-24 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置 |
| JP2963986B2 (ja) * | 1997-11-19 | 1999-10-18 | 工業技術院長 | カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤 |
-
2002
- 2002-10-01 MX MXPA04003040A patent/MXPA04003040A/es not_active Application Discontinuation
- 2002-10-01 JP JP2003532646A patent/JP2005504829A/ja active Pending
- 2002-10-01 CA CA002462443A patent/CA2462443A1/en not_active Abandoned
- 2002-10-01 NZ NZ532327A patent/NZ532327A/en unknown
- 2002-10-01 WO PCT/US2002/031496 patent/WO2003029428A2/en not_active Ceased
- 2002-10-01 AU AU2002341938A patent/AU2002341938B2/en not_active Ceased
- 2002-10-01 PL PL02369104A patent/PL369104A1/xx not_active Application Discontinuation
- 2002-10-01 KR KR10-2004-7004775A patent/KR20040045041A/ko not_active Withdrawn
- 2002-10-01 EP EP02776099A patent/EP1439849A4/en not_active Withdrawn
- 2002-10-01 IL IL16123102A patent/IL161231A0/xx unknown
- 2002-10-01 BR BR0213043-2A patent/BR0213043A/pt not_active IP Right Cessation
- 2002-10-01 US US10/491,323 patent/US7320959B2/en not_active Expired - Fee Related
- 2002-10-01 CN CNA028241010A patent/CN1599622A/zh active Pending
-
2004
- 2004-03-31 NO NO20041331A patent/NO20041331L/no not_active Application Discontinuation
-
2007
- 2007-11-13 US US11/983,987 patent/US7632815B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1439849A2 (en) | 2004-07-28 |
| US7632815B2 (en) | 2009-12-15 |
| NZ532327A (en) | 2005-10-28 |
| AU2002341938B2 (en) | 2007-08-30 |
| US20090011989A1 (en) | 2009-01-08 |
| NO20041331D0 (no) | 2004-03-31 |
| WO2003029428A8 (en) | 2004-04-22 |
| US20040266675A1 (en) | 2004-12-30 |
| NO20041331L (no) | 2004-05-28 |
| CN1599622A (zh) | 2005-03-23 |
| US7320959B2 (en) | 2008-01-22 |
| WO2003029428A3 (en) | 2003-10-30 |
| WO2003029428A2 (en) | 2003-04-10 |
| PL369104A1 (en) | 2005-04-18 |
| MXPA04003040A (es) | 2004-07-15 |
| EP1439849A4 (en) | 2005-09-28 |
| JP2005504829A (ja) | 2005-02-17 |
| KR20040045041A (ko) | 2004-05-31 |
| IL161231A0 (en) | 2004-09-27 |
| CA2462443A1 (en) | 2003-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019085A2 (pt) | Uso de agentes para tratamento de condições respiratórias | |
| Titball et al. | Burkholderia pseudomallei: animal models of infection | |
| BR0005276A (pt) | Compostos para o tratamento de disfução sexual feminina | |
| BRPI0408236A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
| DE69820265D1 (de) | Für den vogelembryo geeignete multivalente impfstoffe | |
| BR0210886A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal | |
| BRPI0509139A (pt) | composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor | |
| BR0214962A (pt) | Composição para tratar distúrbios neurocerebrovasculares | |
| ATE499934T1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| PT1173201E (pt) | Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina | |
| Alabadí et al. | Impairment of the modulatory role of nitric oxide on the endothelin-1-elicited contraction of cerebral arteries: a pathogenetic factor in cerebral vasospasm after subarachnoid hemorrhage? | |
| BR0213743A (pt) | Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição | |
| Grahn et al. | Blockade of alpha1 adrenoreceptors in the dorsal raphe nucleus prevents enhanced conditioned fear and impaired escape performance following uncontrollable stressor exposure in rats | |
| BR0112659A (pt) | Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo | |
| NO930893L (no) | Ultralydformidlet administrering av forbindelser i akvatiske dyr | |
| BRPI0410419A (pt) | tratamento para a ansiedade com ziprasidona | |
| BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
| DE602004024221D1 (de) | Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen | |
| EP1254260A4 (en) | Methods for diagnosing and treating heart disease | |
| BR0110396A (pt) | Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia | |
| DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| MXPA04003040A (es) | Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural. | |
| PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
| BR9916391A (pt) | Compostos de triazineona para o tratamento de doenças causadas por sarcosiste, neopora e toxoplasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |